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Warfarin is the most widely prescribed oral anticoagulant worldwide and a 
major contributor to drug-related morbidity and mortality. Many of the clinical 
and healthcare system-related problems encountered during routine warfarin 
management are amplified in the period following a patient’s discharge from 
hospital, further increasing the risk of adverse outcomes. Hospital-based post-
discharge warfarin management services are limited in their capacity to manage 
all of the patients in need of care, and there is significant geographic variation in 
their availability. It has been demonstrated that pharmacists can successfully 
adopt a variety of roles in warfarin management; making greater use of their 
skills may contribute to reductions in the rates of warfarin-related adverse 
events in the post-discharge period. 
A previous study conducted by Jackson et al. in southern Tasmania 
demonstrated the potential of a pharmacist-delivered, home-based post-
discharge warfarin management service to improve the initiation of warfarin 
therapy and significantly decrease the rates of total bleeding, major bleeding and 
minor bleeding complications in the first three months post-discharge. Patient 
feedback was highly positive, and a cost-analysis estimated that widespread 
implementation of the service would lead to $A5 million per annum in overall 
cost savings to the healthcare system. While this program was highly successful, 
it was believed that the intensity of the four-visit model may not prove 
sustainable for wide scale implementation. 
The objective of this study was to develop and implement a sustainable 
pharmacist-delivered post-discharge warfarin management service to enable the 
smooth transition of both newly anticoagulated patients and those already 
taking warfarin from the hospital to community setting. Patients received either 
two or three home visits in their eight to ten days post-discharge, with point-of-
care (POC) International Normalised Ratio (INR) monitoring and warfarin 
education integrated into the existing Australian government-funded Home 
Medicines Review (HMR) program in an attempt to assure its sustainability. The 
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service was investigated in a prospective, non-randomised controlled cohort 
study. Evaluation of the service included assessment of its clinical and 
educational outcomes, a formal economic analysis and a qualitative study of 
stakeholder satisfaction focussing strongly on the logistical aspects of service 
implementation and delivery. 
Patients were recruited from eight hospital sites in five major centres across three 
Australian states. One hundred and thirty-nine patients received standard 
management by their general practitioner (GP) (‘usual care’) and 129 received 
the post-discharge service. The service was associated with statistically 
significantly reductions in the rates of combined major and minor bleeding 
events (5.3% vs. 14.7%, p=0.03) and combined bleeding and thromboembolic 
events (6.4% vs. 19.0%, p=0.008) to Day 90 post-discharge. Persistence with 
therapy, based on the proportion of patients continuing warfarin at Day 90, 
improved from 83.6% to 95.4% (p=0.004); an improvement in warfarin 
knowledge was also demonstrated. No significant differences in self-reported 
adherence, quality of life, hospital readmission and death rates or INR control 
were observed. The cost-analysis demonstrated that the costs to the healthcare 
system of providing the service were greatly exceeded by reductions in the costs 
of warfarin-related hospital admissions; the service was therefore shown to be 
highly cost-effective in regards to warfarin-related costs. An uncertainty analysis 
indicated that it was cost dominant in approximately 80% of the iterations of the 
model, and business cases suggested that it was a viable prospect from the 
perspectives of both the Australian government and the community pharmacy 
sector. 
The qualitative study identified that the service was popular with patients and 
some elements, such as the warfarin education, were universally recognised as 
beneficial. Major barriers were perceived to the implementation of the service via 
the HMR program, however, especially with respect to the existing referral 
process. Issues were highlighted regarding GP and community pharmacy 
engagement with the service, and the need for improved information technology 
solutions was recognised to promote effective communication between 
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multidisciplinary care providers. Pharmacist workload and remuneration were 
also identified as potentially problematic. As a result of these issues, 
stakeholders considered the current service model largely unviable, promoting 
instead a range of alternative service models. 
In conclusion, this study demonstrated undeniable deficiencies in current 
community-based post-discharge warfarin management practices and positive 
outcomes arising from the post-discharge service. It failed, however, to produce 
sufficient evidence to support its widespread implementation in its current form. 
The optimal method of delivering clinical pharmacy services in the community 
remains uncertain, and new paradigms may need to be explored as 
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